Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or clinical decision-making. However, concerns over the credibility of real-world evidence studies have led to calls for more transparency on the design and conduct of RWE studies.
A joint task force between ISPE and ISPOR created a harmonized protocol template for RWE studies that evaluate a treatment effect and are intended to inform decision-making. The HARPER template provides clarity, structure, and a common denominator regarding the level of operational detail, context, and rationale necessary in a protocol.
HARPER = HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects
Link: https://lnkd.in/erkyU2iT
Four protocol templates were identified for RWE studies:
1. The European Medicines Agency’s (EMA) Guideline on Good Pharmacovigilance Practices (GVP) Module VIII – post-authorizations safety studies (PASS) template,
2. ISPE’s guidelines for good pharmacoepidemiology practice (ISPE GPP) section on protocol development,
3. The National Evaluation System for health Technology (NEST) protocol guidance, and
4. The Structured Template and Reporting Tool for Real World Evidence (STaRT-RWE).
The HARPER protocol contains nine sections, including a title page, abstract, and a table for amendments and updates. Each section includes structured free text, a structured table, or a figure, and a free-text section to lay out context and rationale for scientific choices.
The study design diagram shows the context and rationale for the study setting, time 0 (index date), inclusion criteria, exclusion criteria, variables, exposure, outcome, follow up, covariates, sensitivity analyses, data sources, metadata, and software used in the study.
The data sources section includes a free text component followed by a structured table for specifying data sources. The data sources section can also include a detailed evaluation of the fitness-for-purpose of data source options.
Overall, the HARPER framework is a valuable resource for researchers and clinicians who are planning or conducting RWE studies. The framework can help to ensure that protocols are well-designed and will produce high-quality evidence.
Share this story...
Real World Evidence (RWE) 101 – ‘Interventional’ Clinical Trial vs Non-Interventional Study
RWE 101 - 'Interventional' Clinical Trial vs Non-Interventional Study Interventional Clinical Trial: In this type of study, researchers actively intervene by assigning participants to different groups, administering specific treatments, [...]
Real World Evidence (RWE) 101 – Are the terms ‘clinical study’ and ‘clinical trial’ synonymous in the context of non-interventional studies?
RWE 101 - Are the terms 'clinical study' and 'clinical trial' synonymous in the context of non-interventional studies? No, "clinical study" and "clinical trial" are not necessarily synonymous in [...]
Real World Evidence (RWE) 101 – The Importance of Regulatory Definitions
RWE 101 - The Importance of Regulatory Definitions "Words are powerful"Regulatory definitions are important in the context of real-world evidence (RWE) studies and real-world research for several reasons:[1] Consistency: [...]
Real World Evidence (RWE) 101 – Regulatory Compliance
RWE 101 - Regulatory Compliance Regulatory compliance in the context of real-world evidence (RWE) refers to ensuring that the generation and use of RWE for regulatory purposes [...]
Real World Evidence (RWE) 101 – Regulatory Intelligence
RWE 101 - Regulatory Intelligence In the context of real-world evidence (RWE) and real-world research (RWR), regulatory intelligence refers to the process of gathering, analyzing, and interpreting regulatory information [...]
Real World Evidence (RWE) 101 – Regulatory Science
RWE 101 - Regulatory Science Regulatory science is a field of study that involves the application of scientific methods, principles, and data to the development and evaluation of regulatory [...]







